A new era for the treatment of blood diseases

We are focused on bringing our cell therapy and immunotherapies to patients in
need.

Hemogenyx Pharmaceuticals plc (“Hemogenyx”) is a publicly traded company (LSE: HEMO) headquartered in
London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state-
of-the-art research facility.

For more than 50 years, bone marrow transplantation has been used to save the lives of
patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow
transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted.
Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases,
such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia
and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and
treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx is developing several distinct and complementary products, as
well as a platform technology that it uses as an engine for novel product development.